File(s) not publicly available
Reason: No enhanced material
Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20 mg/5 mg/12.5 mg fixed-dose combination in hypertension: a profile of its use
Any type of resource available online.
Conflicts of interest: K.A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
Funding: The preparation of this review was not supported by any external funding.
Additional information about this Adis Drug Review may be found here.
The triple-component fixed-dose combination of olmesartan medoxomil (OLM)/amlodipine (AML)/hydrochlorothiazide (HCT) is a rational choice for patients who require treatment with three or more antihypertensives. The three drugs in the FDC have complementary mechanisms of action, with OLM, AML and HCT being an angiotensin II receptor blocker, calcium channel blocker and diuretic, respectively. Once-daily OLM/AML/HCT 20 mg/5 mg/12.5 mg reduced systolic and diastolic blood pressure, thereby enabling patients to achieve blood pressure goals, and was generally well tolerated in clinical trials. Moreover, the use of a fixed-dose combination comprising three antihypertensive components reduces pill burden, which may improve patient adherence to treatment and, ultimately, clinical outcomes.
Access to the full article can be found here.
© Springer International Publishing AG, part of Springer Nature 2017